{
    "xml": "<topic id=\"PHP81595\" outputclass=\"clinicalMedicinalProductInformation\" type=\"clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information/prolia\" basename=\"prolia\" title=\"Prolia\">\n<title>Prolia<tm tmtype=\"reg\"/>\n</title>\n<topic id=\"PHP82290\" outputclass=\"indicationsAndDose\" rev=\"1.23\" parent=\"/clinical-medicinal-product-information/prolia\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures</p>\n<p outputclass=\"therapeuticIndication\">Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By subcutaneous injection</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>60&#8239;mg every 6&#8239;months, supplement with calcium and vitamin D.</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP82326\" outputclass=\"nationalFunding\" rev=\"1.8\" parent=\"/clinical-medicinal-product-information/prolia\">\n<title>National funding/access decisions</title>\n<body>\n<section>\n<sectiondiv outputclass=\"smcDecisions\">\n<p outputclass=\"title\">Scottish Medicines Consortium (SMC) Decisions</p>\n<sectiondiv outputclass=\"smcDecision\">\n<sectiondiv>\n<p>The <i>Scottish Medicines Consortium</i> has advised (November 2010) that denosumab (<i>Prolia</i>\n<tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of osteoporosis in postmenopausal women at increased risk of fractures who have a bone mineral density T-score &lt;&#8211;2.5 and &#8805;&#8211;4.0 and for whom bisphosphonates are unsuitable.</p>\n</sectiondiv>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" title=\"Clinical medicinal product information\" namespace=\"/clinical-medicinal-product-information\">Clinical medicinal product information</xref>\n</parents>\n<backlinks/>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"#clinicalMedicinalProductInformation\" href=\"#clinicalMedicinalProductInformation\" namespace=\"/clinical-medicinal-product-information\" title=\"Clinical medicinal product information\" count=\"1\" rel=\"link\">Clinical medicinal product information</xref>\n</links>\n</topic>",
    "id": "PHP81595",
    "outputclass": "clinicalMedicinalProductInformation",
    "type": "clinicalMedicinalProductInformation",
    "namespace": "/clinical-medicinal-product-information/prolia",
    "basename": "prolia",
    "title": "Prolia",
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures",
                        "html": "Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures"
                    },
                    {
                        "textContent": "Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures",
                        "html": "Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures"
                    }
                ],
                "specificity": {
                    "routes": [
                        "subcutaneous injection"
                    ],
                    "textContent": "By subcutaneous injection",
                    "html": "By subcutaneous injection"
                },
                "adult": [
                    {
                        "textContent": "60 mg every 6 months, supplement with calcium and vitamin D.",
                        "html": "<p>60&#8239;mg every 6&#8239;months, supplement with calcium and vitamin D.</p>"
                    }
                ]
            }
        ]
    },
    "nationalFunding": {
        "smcDecisions": [
            {
                "type": "smcDecisions",
                "textContent": "The Scottish Medicines Consortium has advised (November 2010) that denosumab (Prolia ) is accepted for restricted use within NHS Scotland for the treatment of osteoporosis in postmenopausal women at increased risk of fractures who have a bone mineral density T-score <&#8211;2.5 and &#8805;&#8211;4.0 and for whom bisphosphonates are unsuitable.",
                "html": "<p>The <i>Scottish Medicines Consortium</i> has advised (November 2010) that denosumab (<i>Prolia</i> <tm tmtype=\"reg\"/>) is accepted for restricted use within NHS Scotland for the treatment of osteoporosis in postmenopausal women at increased risk of fractures who have a bone mineral density T-score &lt;&#8211;2.5 and &#8805;&#8211;4.0 and for whom bisphosphonates are unsuitable.</p>"
            }
        ]
    },
    "backlinks": {},
    "links": {
        "#clinicalMedicinalProductInformation": [
            {
                "id": "clinicalMedicinalProductInformation",
                "label": "Clinical medicinal product information",
                "type": "#clinicalMedicinalProductInformation"
            }
        ]
    }
}